



## AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference

November 12, 2020

### To feature discussion of the Company's world-leading therapeutic and diagnostic candidates targeting TDP-43

LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in a fireside chat during the upcoming Jefferies Virtual London Healthcare Conference.

The presentation will feature an overview of the Company's business strategy and 2021 product development objectives in alignment with AC Immune's vision for precision medicine for neurodegenerative diseases. The discussion will also feature the Company's early- and late-stage development pipeline with a focus on its novel antibody and diagnostic candidates addressing an emerging target in neurodegenerative diseases, TAR DNA-binding protein 43 (TDP-43).

AC Immune's CEO, Prof. Andrea Pfeifer, Ph.D., will discuss AC Immune's focused strategy for accelerating development of its first-/best-in-class candidates in Alzheimer's disease, as well as key neurodegenerative and non-CNS indications, in order to maximize the value of its pipeline in 2021 and beyond. The presentation will be followed by a question and answer session and will also feature progress made in the Company's TDP-43-targeted therapeutic and diagnostic programs, which are among the most advanced in the world. TDP-43 is an emerging neuropathology that plays a key role in AD, as well as a number of NeuroOrphan indications such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 pathology (FLTD-TDP). A more recently described dementia, limbic-predominant age-related TDP-43 encephalopathy (LATE), is a highly prevalent Alzheimer's-like dementia. TDP-43 neuropathological changes underlying LATE, are present in 20–50% of individuals over 80 years old<sup>1</sup> and AC Immune's therapeutic antibody and diagnostic imaging agent could be the first in the world to enable a precision medicine approach to this important disease driver.

Jefferies Virtual London Healthcare Conference

Date: November 18, 2020 | 6:45–7:15 am ET / 11:45am–12:15 pm GMT

Format: Virtual Presentation followed by Q&A

Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

A webcast of the presentation will be available on the [Events Page](#) of AC Immune's website.

<sup>1</sup> 2019, Nelson *et al.* Consensus working group report

### About AC Immune SA

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

### For further information, please contact:

#### Head of Investor Relations

Joshua Drumm, Ph.D.

AC Immune

Phone: +1 917 809 0814

Email: [joshua.drumm@acimmune.com](mailto:joshua.drumm@acimmune.com)

#### US Media

Katie Gallagher

LaVoie Health Science

Phone: +1 617 792 3937

Email: [kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

#### Global Head of Communications

Judith Moore

AC Immune

Phone: +41 79 826 63 82

Email: [judith.moore@acimmune.com](mailto:judith.moore@acimmune.com)

#### European Investors & Media

Chris Maggos

LifeSci Advisors

Phone: +41 79 367 6254

Email: [chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

### Forward looking statements

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3.

Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.



Source: AC Immune SA